{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:14:51Z","timestamp":1770596091964,"version":"3.49.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T00:00:00Z","timestamp":1390348800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-244x-14-16","type":"journal-article","created":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T18:27:04Z","timestamp":1390415224000},"source":"Crossref","is-referenced-by-count":9,"title":["Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada"],"prefix":"10.1186","volume":"14","author":[{"given":"Jean","family":"Lachaine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Beauchemin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Mathurin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maud","family":"Beillat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,22]]},"reference":[{"issue":"Suppl 4","key":"1532_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1528-1167.2005.463003.x","volume":"46","author":"M Bauer","year":"2005","unstructured":"Bauer M, Pfennig A: Epidemiology of bipolar disorders. Epilepsia. 2005, 46 (Suppl 4): 8-13.","journal-title":"Epilepsia"},{"issue":"5","key":"1532_CR2","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1056\/NEJMra035354","volume":"351","author":"RH Belmaker","year":"2004","unstructured":"Belmaker RH: Bipolar disorder. N Engl J Med. 2004, 351 (5): 476-486. 10.1056\/NEJMra035354.","journal-title":"N Engl J Med"},{"issue":"1","key":"1532_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/jclp.20333","volume":"63","author":"JL Culver","year":"2007","unstructured":"Culver JL, Arnow BA, Ketter TA: Bipolar disorder: improving diagnosis and optimizing integrated care. J Clin Psychol. 2007, 63 (1): 73-92. 10.1002\/jclp.20333.","journal-title":"J Clin Psychol"},{"issue":"1","key":"1532_CR4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/070674370605100104","volume":"51","author":"A Schaffer","year":"2006","unstructured":"Schaffer A, Cairney J, Cheung A, Veldhuizen S, Levitt A: Community survey of bipolar disorder in Canada: lifetime prevalence and illness characteristics. Can J Psychiatry. 2006, 51 (1): 9-16.","journal-title":"Can J Psychiatry"},{"issue":"2","key":"1532_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0165-0327(99)00129-9","volume":"59","author":"MA Oquendo","year":"2000","unstructured":"Oquendo MA, Waternaux C, Brodsky B, Parsons B, Haas GL, Malone KM, Mann JJ: Suicidal behavior in bipolar mood disorder: clinical characteristics of attempters and nonattempters. J Affect Disord. 2000, 59 (2): 107-117. 10.1016\/S0165-0327(99)00129-9.","journal-title":"J Affect Disord"},{"issue":"9063","key":"1532_CR6","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/S0140-6736(96)07495-8","volume":"349","author":"CJ Murray","year":"1997","unstructured":"Murray CJ, Lopez AD: Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997, 349 (9063): 1436-1442. 10.1016\/S0140-6736(96)07495-8.","journal-title":"Lancet"},{"key":"1532_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1192\/bjp.180.3.227","volume":"180","author":"R Das Gupta","year":"2002","unstructured":"Das Gupta R, Guest JF: Annual cost of bipolar disorder to UK society. Br J Psychiatry. 2002, 180: 227-233. 10.1192\/bjp.180.3.227.","journal-title":"Br J Psychiatry"},{"issue":"11","key":"1532_CR8","first-page":"757","volume":"14","author":"KE Laxman","year":"2008","unstructured":"Laxman KE, Lovibond KS, Hassan MK: Impact of bipolar disorder in employed populations. Am J Manag Care. 2008, 14 (11): 757-764.","journal-title":"Am J Manag Care"},{"issue":"1","key":"1532_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4088\/JCP.v66n0116","volume":"66","author":"CL Bowden","year":"2005","unstructured":"Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, Vagero M, Svensson K: A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005, 66 (1): 111-121. 10.4088\/JCP.v66n0116.","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"1532_CR10","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1176\/appi.ajp.162.7.1351","volume":"162","author":"JR Calabrese","year":"2005","unstructured":"Calabrese JR, Keck PE, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J: A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005, 162 (7): 1351-1360. 10.1176\/appi.ajp.162.7.1351.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"1532_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2165\/11538350-000000000-00000","volume":"28","author":"TC Woodward","year":"2010","unstructured":"Woodward TC, Tafesse E, Quon P, Lazarus A: Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder. Pharmacoeconomics. 2010, 28 (9): 751-764. 10.2165\/11538350-000000000-00000.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1532_CR12","doi-asserted-by":"crossref","first-page":"322","DOI":"10.18553\/jmcp.2006.12.4.322","volume":"12","author":"NW Calvert","year":"2006","unstructured":"Calvert NW, Burch SP, Fu AZ, Reeves P, Thompson TR: The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder. J Manag Care Pharm. 2006, 12 (4): 322-330.","journal-title":"J Manag Care Pharm"},{"issue":"6","key":"1532_CR13","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1177\/0269881106068395","volume":"21","author":"J McKendrick","year":"2007","unstructured":"McKendrick J, Cerri KH, Lloyd A, D'Ausilio A, Dando S, Chinn C: Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom. J Psychopharmacol. 2007, 21 (6): 588-596.","journal-title":"J Psychopharmacol"},{"issue":"Pt 1","key":"1532_CR14","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.clinthera.2009.06.009","volume":"31","author":"L Fajutrao","year":"2009","unstructured":"Fajutrao L, Paulsson B, Liu S, Locklear J: Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis. Clin Ther. 2009, 31 (Pt 1): 1456-1468.","journal-title":"Clin Ther"},{"issue":"3","key":"1532_CR15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1600-0447.2011.01716.x","volume":"124","author":"F Kasteng","year":"2011","unstructured":"Kasteng F, Eriksson J, Sennfalt K, Lindgren P: Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta Psychiatr Scand. 2011, 124 (3): 214-225. 10.1111\/j.1600-0447.2011.01716.x.","journal-title":"Acta Psychiatr Scand"},{"issue":"7","key":"1532_CR16","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/j.1399-5618.2009.00748.x","volume":"11","author":"RS McIntyre","year":"2009","unstructured":"McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J: A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009, 11 (7): 673-686. 10.1111\/j.1399-5618.2009.00748.x.","journal-title":"Bipolar Disord"},{"issue":"8","key":"1532_CR17","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/j.1399-5618.2009.00749.x","volume":"11","author":"RS McIntyre","year":"2009","unstructured":"McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J: Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord. 2009, 11 (8): 815-826. 10.1111\/j.1399-5618.2009.00749.x.","journal-title":"Bipolar Disord"},{"issue":"1\u20132","key":"1532_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jad.2009.12.028","volume":"122","author":"RS McIntyre","year":"2010","unstructured":"McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J: Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010, 122 (1\u20132): 27-38.","journal-title":"J Affect Disord"},{"issue":"3","key":"1532_CR19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jad.2010.04.005","volume":"126","author":"RS McIntyre","year":"2010","unstructured":"McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J: Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord. 2010, 126 (3): 358-365. 10.1016\/j.jad.2010.04.005.","journal-title":"J Affect Disord"},{"issue":"6","key":"1532_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/MLR.0b013e318040ad90","volume":"45","author":"FR Johnson","year":"2007","unstructured":"Johnson FR, Ozdemir S, Manjunath R, Hauber AB, Burch SP, Thompson TR: Factors that affect adherence to bipolar disorder treatments: a stated-preference approach. Med Care. 2007, 45 (6): 545-552. 10.1097\/MLR.0b013e318040ad90.","journal-title":"Med Care"},{"issue":"5","key":"1532_CR21","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/oby.2005.109","volume":"13","author":"Y Oguma","year":"2005","unstructured":"Oguma Y, Sesso HD, Paffenbarger RS, Lee IM: Weight change and risk of developing type 2 diabetes. Obes Res. 2005, 13 (5): 945-951. 10.1038\/oby.2005.109.","journal-title":"Obes Res"},{"issue":"6","key":"1532_CR22","first-page":"461","volume":"273","author":"WC Willett","year":"1995","unstructured":"Willett WC, Manson JE, Stampfer MJ, Colditz GA, Rosner B, Speizer FE, Hennekens CH: Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range. JAMA. 1995, 273 (6): 461-465.","journal-title":"Risk within the 'normal' weight range. JAMA"},{"issue":"11","key":"1532_CR23","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1038\/oby.2008.396","volume":"16","author":"PT Williams","year":"2008","unstructured":"Williams PT: Increases in weight and body size increase the odds for hypertension during 7 years of follow-up. Obesity (Silver Spring). 2008, 16 (11): 2541-2548. 10.1038\/oby.2008.396.","journal-title":"Obesity (Silver Spring)"},{"issue":"2","key":"1532_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7326\/0003-4819-128-2-199801150-00001","volume":"128","author":"Z Huang","year":"1998","unstructured":"Huang Z, Willett WC, Manson JE, Rosner B, Stampfer MJ, Speizer FE, Colditz GA: Body weight, weight change, and risk for hypertension in women. Ann Intern Med. 1998, 128 (2): 81-88. 10.7326\/0003-4819-128-2-199801150-00001.","journal-title":"Ann Intern Med"},{"issue":"4","key":"1532_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/oxfordjournals.aje.a009460","volume":"147","author":"DJ Galanis","year":"1998","unstructured":"Galanis DJ, Harris T, Sharp DS, Petrovitch H: Relative weight, weight change, and risk of coronary heart disease in the Honolulu Heart Program. Am J Epidemiol. 1998, 147 (4): 379-386. 10.1093\/oxfordjournals.aje.a009460.","journal-title":"Am J Epidemiol"},{"issue":"7","key":"1532_CR26","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1161\/STROKEAHA.109.547869","volume":"40","author":"K Asplund","year":"2009","unstructured":"Asplund K, Karvanen J, Giampaoli S, Jousilahti P, Niemela M, Broda G, Cesana G, Dallongeville J, Ducimetriere P, Evans A, et al: Relative risks for stroke by age, sex, and population based on follow-up of 18 European populations in the MORGAM Project. Stroke. 2009, 40 (7): 2319-2326. 10.1161\/STROKEAHA.109.547869.","journal-title":"Stroke"},{"issue":"6","key":"1532_CR27","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.2337\/diacare.28.6.1339","volume":"28","author":"LE Egede","year":"2005","unstructured":"Egede LE, Nietert PJ, Zheng D: Depression and all-cause and coronary heart disease mortality among adults with and without diabetes. Diabetes Care. 2005, 28 (6): 1339-1345. 10.2337\/diacare.28.6.1339.","journal-title":"Diabetes Care"},{"key":"1532_CR28","first-page":"28","volume-title":"Chronic Disease Surveillance Division","author":"Public Health Agency of Canada","year":"2010","unstructured":"Public Health Agency of Canada: Report from the Canadian Chronic Disease Surveillance System: Hypertension in Canada, 2010. Chronic Disease Surveillance Division. 2010, Ottawa: Public Health Agency of Canada, 28-Available from: http:\/\/www.phac-aspc.gc.ca\/cd-mc\/cvd-mcv\/ccdss-snsmc-2010\/pdf\/CCDSS_HTN_Report_FINAL_EN_20100513.pdf ."},{"issue":"2","key":"1532_CR29","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/archinte.161.2.242","volume":"161","author":"PA Lotufo","year":"2001","unstructured":"Lotufo PA, Gaziano JM, Chae CU, Ajani UA, Moreno-John G, Buring JE, Manson JE: Diabetes and all-cause and coronary heart disease mortality among US male physicians. Arch Intern Med. 2001, 161 (2): 242-247. 10.1001\/archinte.161.2.242.","journal-title":"Arch Intern Med"},{"issue":"9","key":"1532_CR30","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.amjcard.2004.12.061","volume":"95","author":"E Biagini","year":"2005","unstructured":"Biagini E, Elhendy A, Schinkel AF, Rizzello V, van Domburg RT, Krenning BJ, Schouten O, Sozzi FB, Branzi A, Rocchi G, et al: Comparison of all-cause mortality in women with known or suspected coronary artery disease referred for dobutamine stress echocardiography with normal versus abnormal test results. Am J Cardiol. 2005, 95 (9): 1072-1075. 10.1016\/j.amjcard.2004.12.061.","journal-title":"Am J Cardiol"},{"issue":"9","key":"1532_CR31","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1161\/hs0901.094253","volume":"32","author":"H Bronnum-Hansen","year":"2001","unstructured":"Bronnum-Hansen H, Davidsen M, Thorvaldsen P: Long-term survival and causes of death after stroke. Stroke. 2001, 32 (9): 2131-2136. 10.1161\/hs0901.094253.","journal-title":"Stroke"},{"issue":"2\u20133","key":"1532_CR32","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jad.2005.03.017","volume":"87","author":"DA Revicki","year":"2005","unstructured":"Revicki DA, Hanlon J, Martin S, Gyulai L, Nassir Ghaemi S, Lynch F, Mannix S, Kleinman L: Patient-based utilities for bipolar disorder-related health states. J Affect Disord. 2005, 87 (2\u20133): 203-210.","journal-title":"J Affect Disord"},{"issue":"4","key":"1532_CR33","first-page":"41","volume":"14","author":"SE Schultz","year":"2003","unstructured":"Schultz SE, Kopec JA: Impact of chronic conditions. Health Rep. 2003, 14 (4): 41-53.","journal-title":"Health Rep"},{"key":"1532_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1192\/bjp.170.3.205","volume":"170","author":"EC Harris","year":"1997","unstructured":"Harris EC, Barraclough B: Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry. 1997, 170: 205-228. 10.1192\/bjp.170.3.205.","journal-title":"A meta-analysis. Br J Psychiatry"},{"issue":"4","key":"1532_CR35","first-page":"138","volume":"43","author":"J Schoemaker","year":"2010","unstructured":"Schoemaker J, Naber D, Vrijland P, Panagides J, Emsley R: Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010, 43 (4): 138-146.","journal-title":"Olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry"},{"issue":"12","key":"1532_CR36","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353 (12): 1209-1223. 10.1056\/NEJMoa051688.","journal-title":"N Engl J Med"},{"issue":"7","key":"1532_CR37","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1176\/ajp.2007.164.7.1050","volume":"164","author":"JP McEvoy","year":"2007","unstructured":"McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD: Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007, 164 (7): 1050-1060. 10.1176\/appi.ajp.164.7.1050.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"1532_CR38","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","volume":"163","author":"TS Stroup","year":"2006","unstructured":"Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, et al: Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006, 163 (4): 611-622. 10.1176\/appi.ajp.163.4.611.","journal-title":"Am J Psychiatry"},{"key":"1532_CR39","volume-title":"Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update) [Internet]","author":"National Collaborating Centre for Mental Health (UK)","year":"2009","unstructured":"National Collaborating Centre for Mental Health (UK): Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update) [Internet]. 2009, Leicester (UK): British Psychological Society, Mar. (NICE Clinical Guidelines, No. 82.) Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK11681\/"},{"key":"1532_CR40","unstructured":"Consumer Price Index, Health Care: CANSIM Table 326\u20130020."},{"key":"1532_CR41","unstructured":"R\u00e9gie de l'assurance maladie du Qu\u00e9bec: List of Medications. Last updated on 3 October 2013. Quebec?: Biblioth\u00e8que et Archives nationales du Qu\u00e9bec, 2011. Available from: https:\/\/www.prod.ramq.gouv.qc.ca\/DPI\/PO\/Commun\/PDF\/Liste_Med\/Liste_Med\/liste_med_2011_10_03_en.pdf , 33"},{"key":"1532_CR42","volume-title":"Manuel des m\u00e9decins sp\u00e9cialistes","author":"R\u00e9gie de l'assurance maladie du Qu\u00e9bec","year":"2011","unstructured":"R\u00e9gie de l'assurance maladie du Qu\u00e9bec: Manuel des m\u00e9decins sp\u00e9cialistes. 2011"},{"key":"1532_CR43","volume-title":"Tracking Heart Disease and Stroke in Canada","author":"Public Health Agency of Canada","year":"2009","unstructured":"Public Health Agency of Canada: Tracking Heart Disease and Stroke in Canada. 2009, Ottawa"},{"key":"1532_CR44","volume-title":"Economic Cost of Chronic Disease in Canada: 1995\u20132003","author":"J Patra","year":"2007","unstructured":"Patra J, Popova S, Rhem J, Bondy S, Flint R, Giesbrecht N: Economic Cost of Chronic Disease in Canada: 1995\u20132003. 2007"},{"key":"1532_CR45","volume-title":"The Growing Burden of Heart Disease and Stroke in Canada 2003","author":"Heart and Stroke Foundation of Canada","year":"2003","unstructured":"Heart and Stroke Foundation of Canada: The Growing Burden of Heart Disease and Stroke in Canada 2003. 2003, Ottawa, Canada, In vol. 1-896242-30-8"},{"key":"1532_CR46","volume-title":"Diabetes in Canada:Highlights from the National Diabetes Surveillance System 2004 \u2013 2005","author":"Public Health Agency of Canada","year":"2008","unstructured":"Public Health Agency of Canada: Diabetes in Canada:Highlights from the National Diabetes Surveillance System 2004 \u2013 2005. 2008, Ottawa: PHAC"},{"key":"1532_CR47","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3111\/200508147167","volume":"8","author":"R Goeree","year":"2005","unstructured":"Goeree R, Blackhouse R, Petrovic R, Salama S: Cost of stroke in Canada: a 1-year prospective study. J Med Econ. 2005, 8: 147-167. 10.3111\/200508147167.","journal-title":"J Med Econ"},{"issue":"13 Suppl 1","key":"1532_CR48","first-page":"7S","volume":"50","author":"Canadian Psychiatric Association","year":"2005","unstructured":"Canadian Psychiatric Association: Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry. 2005, 50 (13 Suppl 1): 7S-57S.","journal-title":"Can J Psychiatry"},{"issue":"1","key":"1532_CR49","first-page":"29","volume":"10","author":"K Wilkins","year":"1998","unstructured":"Wilkins K, Park E: Home care in Canada. Health Rep. 1998, 10 (1): 29-37. ENG); 31-40(FRE","journal-title":"Health Rep"},{"issue":"1","key":"1532_CR50","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.schres.2003.10.010","volume":"71","author":"LA Lenert","year":"2004","unstructured":"Lenert LA, Sturley AP, Rapaport MH, Chavez S, Mohr PE, Rupnow M: Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res. 2004, 71 (1): 155-165. 10.1016\/j.schres.2003.10.010.","journal-title":"Schizophr Res"},{"key":"1532_CR51","volume-title":"Life Tables, Canada, provinces and territories, 2000\u20132002 (Catalogue no. 84-537-XIE)","author":"Statistics Canada","year":"2006","unstructured":"Statistics Canada: Life Tables, Canada, provinces and territories, 2000\u20132002 (Catalogue no. 84-537-XIE). 2006, Ottawa: Minister of Industry E"},{"key":"1532_CR52","volume-title":"Death and mortality rates, by selected groupes causes, age, group and sex, Table 102\u20130551 (Catalogue no. 84F0209X)","author":"Statistics Canada","year":"2007","unstructured":"Statistics Canada: Death and mortality rates, by selected groupes causes, age, group and sex, Table 102\u20130551 (Catalogue no. 84F0209X). Edited by: Minister of Industry. 2007, Ottawa"},{"issue":"4","key":"1532_CR53","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/j.1365-2753.2009.01189.x","volume":"16","author":"RS McIntyre","year":"2010","unstructured":"McIntyre RS, Cragin L, Sorensen S, Naci H, Baker T, Roussy JP: Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. J Eval Clin Pract. 2010, 16 (4): 744-755. 10.1111\/j.1365-2753.2009.01189.x.","journal-title":"J Eval Clin Pract"},{"issue":"7","key":"1532_CR54","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/j.1399-5618.2008.00625.x","volume":"10","author":"CU Correll","year":"2008","unstructured":"Correll CU, Frederickson AM, Kane JM, Manu P: Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord. 2008, 10 (7): 788-797. 10.1111\/j.1399-5618.2008.00625.x.","journal-title":"Bipolar Disord"},{"issue":"4 Pt 3","key":"1532_CR55","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1080\/15622970903079507","volume":"10","author":"T Treuer","year":"2009","unstructured":"Treuer T, Hoffmann VP, Chen AK, Irimia V, Ocampo M, Wang G, Singh P, Holt S: Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study. World J Biol Psychiatry. 2009, 10 (4 Pt 3): 729-740.","journal-title":"World J Biol Psychiatry"},{"issue":"7","key":"1532_CR56","doi-asserted-by":"publisher","first-page":"820","DOI":"10.2337\/diacare.15.7.820","volume":"15","author":"P Koskinen","year":"1992","unstructured":"Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992, 15 (7): 820-825. 10.2337\/diacare.15.7.820.","journal-title":"Diabetes Care"},{"issue":"6","key":"1532_CR57","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/archinte.1991.00400060077013","volume":"151","author":"JE Manson","year":"1991","unstructured":"Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, Arky RA, Speizer FE, Hennekens CH: A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med. 1991, 151 (6): 1141-1147. 10.1001\/archinte.1991.00400060077013.","journal-title":"Arch Intern Med"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-14-16.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-14-16\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-14-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T08:35:24Z","timestamp":1648110924000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-14-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,22]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1532"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-14-16","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,22]]},"article-number":"16"}}